EMA Advances Use Of Real-World Data By HTAs And Payers

Results from the first pilot real-world evidence study commissioned by the European Medicines Agency to help HTA bodies and payers characterize patients with multiple myeloma have drawn positive feedback.

Hand holding global network connection on healthcare, telemedicine, wearable devices, health informatics, digital health, technology and futuristic innovations.
The EMA is using RWD to help a diverse range of decision-makers across the medicinal product’s life cycle • Source: Shutterstock

Health technology assessment and payer organizations have begun tapping into the real-world data (RWD) analysis capabilities of the EU medicines network to gain valuable insights for their own decision-making processes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Real-World Evidence

More from Clinical Trials